New Delhi, India: Zydus Cadila, a pharmaceutical company, said on Monday that it has obtained final clearance from the US Food and Drug Administration to commercialise Tofacitinib extended-release tablets, which are used to treat rheumatoid arthritis. The medication has been approved by the US Food and Drug Administration (USFDA) in 11 mg and 22 mg doses, according to the firm.
According to Zydus, the firm was the first to file an abbreviated new drug application (ANDA) for Tofacitinib extended-release tablets 22 mg and so has 180-day exclusivity on this strength.
New Delhi, India: Zydus Cadila, a pharmaceutical company, said on Monday that it has obtained final clearance from the US Food and Drug Administration to commercialise Tofacitinib extended-release tablets, which are used to treat rheumatoid arthritis. The medication has been approved by the US Food and Drug Administration (USFDA) in 11 mg and 22 mg doses, according to the firm.
According to Zydus, the firm was the first to file an abbreviated new drug application (ANDA) for Tofacitinib extended-release tablets 22 mg and so has 180-day exclusivity on this strength.
Explore the profound effects of excessive screen time on your child’s behavior and development. Discover…
Discover how simple daily changes in your diet and lifestyle can significantly improve your heart…
This article explores the common misconception that brain tumours primarily affect older adults, revealing the…
The first-ever ovarian cancer vaccine is poised to change the landscape of women's health by…
As dengue and chikungunya cases rise in Delhi during the monsoon season, understanding prevention strategies…
Skincare is a significant concern for women (and increasingly, men), with the quest for perfect,…